VivaChek Biotech Secures New Round of Financing to Advance Glucose Monitoring and POCT Innovation

Recently, VivaChek announced the completion of a new round of financing amounting to tens of millions of RMB, with Jianwei Capital serving as the exclusive financial advisor for this transaction. Previously, VivaChek had received investments from institutions such as GTJA Capital and Langtaosha.

VCBeat (WeChat ID: vcbeat) has learned that, following this round of financing, VivaChek will strengthen the R&D of blood glucose monitoring and POCT products and enhance its market operational capabilities, further consolidating its expansion capabilities in overseas and Chinese markets, with the aim of entering the capital market within the next 3–5 years.

VivaChek, founded in 2013, has established its foothold in blood glucose monitoring—the largest segment of the POCT market—and is committed to becoming a global leader in the POCT industry.

In May 2015, VivaChek, which had been established for only two years, obtained its first CE certificate and subsequently acquired more than 20 CE certificates over the next four years.

Today, VivaChek’s POCT products are sold in more than 70 countries, including Germany, Italy, the United Kingdom, and the United States, and have been included in the reimbursement formularies of major European healthcare markets. As one of China’s largest POCT exporters to Europe, the company has an annual production capacity of 500 million test strips.

VivaChek’s three founders have cultivated deep expertise in the industry for many years, leveraging a global perspective, forward-thinking mindset, and acute market sensitivity to accurately predict industry transformations. From the outset of product development, VivaChek targeted the European and American markets, establishing and implementing technical specifications and quality systems in strict accordance with European and U.S. standards. This approach created substantial technological barriers, with multiple product performance indicators significantly surpassing those of competitors. In 2016, when the European Union officially raised accuracy standards for blood glucose meters across the board, the company was able to rapidly enter the European market and seize first-mover advantage, thanks to its proactive development of products compliant with the new regulatory requirements.

Talent advantages ensure the continuous innovative development of VivaChek. The R&D team at VivaChek boasts over a decade of extensive experience in POCT development, currently comprising nearly 100 core researchers, including returnees from overseas and holders of master’s and doctoral degrees. This dynamic team demonstrates robust capabilities in technological innovation and output. Meanwhile, VivaChek has earned numerous honors, such as Provincial R&D Center, National Technology-Based SME, and National High-Tech Enterprise, and has undertaken multiple projects, including those under the Zhejiang Provincial Key R&D Program.

Aiming to become a world-class POCT enterprise, VivaChek is continuously enhancing its product portfolio. In the field of blood glucose monitoring, the company has successively launched Bluetooth-enabled blood glucose meters, hospital-specific POC blood glucose meters capable of reading patient wristband information and integrating with hospital HIS/LIS systems, and an integrated in-hospital and out-of-hospital blood glucose (chronic disease) management system. Recently, it obtained domestic certification for a GSM touch-screen color display blood glucose meter, which enables automatic and timely data sharing with family members, physicians, and others via mobile networks, actively supporting mobile chronic disease management in China. Building on its comprehensive blood glucose monitoring product line, the company will rapidly expand into multi-analyte monitoring products covering blood glucose, blood ketones, and blood lipids, as well as cutting-edge solutions such as Continuous Glucose Monitoring Systems (CGMS).

In the POCT sector, VivaChek will enter the market through its quantitative immunofluorescence platform and actively expand into areas such as infectious diseases, cardiology, nephrology, and oncology. Currently, nearly 20 of VivaChek’s products have received CE or CFDA approval.

In the future, VivaChek will continue to actively expand into the U.S. market while deepening its presence in Europe. The domestic market in China is also a key focus for VivaChek following its recent financing round. Against the backdrop of import substitution, the advancement of medical consortiums, and the decentralization of chronic disease management, VivaChek is well-positioned to capture market share and provide Chinese patients with more professional and effective POCT products.